Coeptis Therapeutics Inc.

NASDAQ: COEP · Real-Time Price · USD
13.96
2.48 (21.60%)
At close: Aug 15, 2025, 3:59 PM
13.81
-1.11%
After-hours: Aug 15, 2025, 06:35 PM EDT

Coeptis Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
1.93M 1.86M 1.5M 1.5M 1.5M 1.5M n/a n/a n/a n/a n/a 9.89K 9.89K 84.89K 84.89K 75K 75K
Cost of Revenue
1.66M 1.86M 1.18M 1M 1M 1M 1M 750.96K 500.65K 250.35K n/a 1.49K 1.49K 1.49K 1.49K n/a n/a
Gross Profit
267.93K n/a 319.82K 500.81K 500.72K 500.62K -1M -750.96K -500.65K -250.35K n/a 8.4K 8.4K 83.4K 83.4K 75K 75K
Operating Income
-11.19M -10.05M -11.26M -16.95M -17.76M -21.28M -20.96M -18.7M -24.87M -34.2M -34.11M -35.49M -28.3M -14.23M -11.76M -4.82M -2.2M
Interest Income
n/a n/a n/a n/a n/a n/a n/a 146.06K 146.06K 146.06K 147.98K 1.92K 1.92K 1.92K n/a n/a n/a
Pretax Income
-11.3M -10.88M -11.62M -16.05M -16.13M -21M -20.19M -19.57M -26.26M -37.57M -37.47M -37.77M -30.68M -13.45M -11.1M -5.17M -2.45M
Net Income
-9.87M -9.81M -11.62M -16.05M -16.13M -22.39M -21.47M -20.94M -27.63M -3,408.6B -3,408.6B -3,408.6B -3,408.6B -13.45M -11.1M -5.17M -2.45M
Selling & General & Admin
7.84M 9.36M 7.26M 9M 10.04M 14.57M 15.69M 18.35M 24.88M 34.18M 34M 35.26M 28.1M 14.12M 11.09M 4.34M 1.76M
Research & Development
1.64M 2.33M 3M 7.17M 7.15M 6.4M 5.41M 444.55K 67.51K 41.77K 20.89K n/a n/a n/a n/a n/a n/a
Other Expenses
3.82M 250K 250K -38.6K -38.6K -38.57K 280.13K 318.74K 313.74K 313.7K -5K -5K n/a n/a 482.85K 482.85K 482.85K
Operating Expenses
13.3M 11.94M 10.51M 16.18M 17.19M 20.97M 21.08M 18.78M 24.93M 34.2M 34.02M 35.26M 28.1M 14.12M 11.57M 4.82M 2.24M
Interest Expense
45.49K 317.49K 331.32K 300.19K 276.77K 107.69K 136.2K 172.82K 194.01K 218.41K 98.74K 230.88K 210.15K 189.07K 264.52K 75.96K 32.86K
Selling & Marketing Expenses
-1.52M n/a 1.63M 1.64M 1.64M 12.71K 14.13K 4.58K 8.33K 8.33K 6.91K 4.05K n/a 2.92K -475.42K -475.42K -475.42K
Cost & Expenses
14.53M 13.38M 11.26M 16.93M 17.7M 21.22M 21.08M 18.78M 24.93M 34.2M 34.02M 35.26M 28.1M 14.12M 11.57M 4.82M 2.24M
Income Tax Expense
-1.43M -1.06M -1.41M -1.43M -1.39M n/a 1.31M 1.41M 1.43M 3,408.6B 3,408.6B 3,408.6B 3,408.6B n/a -55.13K -55.13K -55.13K
Shares Outstanding (Basic)
3.07M 1.92M 39.81M 37.57M 35.54M 35.33M 26.65M 21.81M 20.08M 14.3M 19.52M 20.44M 20.44M 9.38M 20.44M 20.44M 20.44M
Shares Outstanding (Diluted)
3.07M 1.92M 39.81M 37.57M 35.54M 35.33M 26.65M 21.81M 20.08M 14.3M 20.44M 20.44M 20.44M 9.38M 20.44M 20.44M 20.44M
EPS (Basic)
2.85 3.88 -0.32 -0.51 -0.56 -0.94 -1.03 -1.09 -1.43 -166.75K -166.75K -166.75K -166.75K -0.82 -302.54 -310.9 -310.77
EPS (Diluted)
2.85 3.88 -0.32 -0.51 -0.56 -0.94 -1.03 -1.08 -1.42 -166.75K -166.75K -166.75K -166.75K -0.82 -302.54 -310.9 -310.77
EBITDA
-10.95M -9.44M -10.26M -14.84M -15.03M -20.16M -19.32M -18.58M -25.16M -32.95M -32.77M -34.37M -27.56M -14.01M -28.81M -21.88M -19.21M
EBIT
-7.68M -10.48M -11.56M -16.11M -16.3M -21.43M -20.32M -19.58M -26.16M -37.36M -37.37M -37.54M -30.47M -13.26M -27.62M -21.88M -19.21M
Depreciation & Amortization
-250.21K n/a 1.03M 1M 1M 1M 1M 1M 1M 1M 1.2M 947.26K 697.28K 447.41K 56.34K 108.73K 108.36K